Pulse Biosciences Shares Rocket on Successful Cardiac Catheter Data

The nPulse Cardiac Catheter demonstrated a 100% procedural success rate at the six-month mark, according to the company’s report. This figure remained robust at the one-year follow-up, with 96% of patients maintaining successful outcomes. The study focused on pulmonary vein isolation, a standard procedure for managing atrial fibrillation, using the company’s proprietary technology to deliver targeted treatment.

Clinical Safety and Market Impact

Market reaction was immediate, with shares climbing to $19.48 in morning trading. This rally provides a significant cushion for the stock, which had previously declined 11% over the past year. While the study reported high efficacy, it also noted that 1.3% of participants experienced a serious adverse effect related to the primary endpoint.

Vivek Reddy, a co-lead investigator for the study, stated that the 12-month data confirms a strong safety profile and suggests the system could considerably advance standard care for atrial fibrillation. The results position Pulse Biosciences to move forward with further regulatory milestones for its ablation technology.